Protein Structural Form Detection via pH-Controlled Elution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases like Alzheimer's and Parkinson's are inadequate for early detection and stratification, leading to delayed and ineffective treatment, and existing blood-based biomarker techniques struggle with low sensitivity and specificity due to protein aggregation interference.
Innovation Solution
A method involving binding proteins to a surface, eluting specific structural forms using pH-adjusted conditions, and detecting these forms using immunological techniques to analyze monomeric, oligomeric, and aggregated proteins in blood samples, preserving the integrity of oligomers and aggregates during elution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard immunoassay protocols are used to detect protein biomarkers in blood, then the detection process is simple and routine, but the sensitivity is insufficient due to low concentration of biomarkers and interference from protein aggregation
Solution Approach 1:
The detection process is segmented into distinct stages: capture of aggregated protein forms on solid phase, selective elution under controlled pH conditions to maintain aggregate integrity, and separate detection of different protein structural forms. This segmentation allows each stage to be optimized independently, improving overall sensitivity without requiring complete redesign of the entire system.
Solution Approach 2:
The method performs preliminary capture and concentration of protein biomarkers from blood samples before detection. By pre-concentrating the low-abundance biomarkers and removing interfering substances during the capture and elution steps, the sensitivity of subsequent detection is significantly enhanced without requiring more complex detection instrumentation.
2Reliability
If harsh elution conditions are used to release proteins from binding surfaces, then elution efficiency is high, but protein aggregates and oligomers are dissociated into monomers, losing structural information
Solution Approach 1:
The elution process utilizes controlled changes in pH parameters to achieve selective release of proteins while maintaining their structural integrity. By adjusting pH to specific ranges that disrupt protein-surface binding interactions without denaturing protein-protein interactions, the method preserves aggregate and oligomer structures during elution, enabling reliable detection of structural forms while maintaining adequate elution efficiency.
3Loss of time
If early detection methods are implemented for neurodegenerative diseases, then treatment can begin earlier for better outcomes, but current diagnostic accuracy is insufficient for reliable early stage detection
Solution Approach 1:
The method employs solid phase capture agents as intermediaries to concentrate and pre-process protein biomarkers from blood samples. This intermediary step enhances the concentration of early-stage biomarkers and removes interfering substances, thereby improving diagnostic accuracy for early detection without requiring more sensitive (and complex) detection instrumentation.
Solution Approach 2:
The detection method applies different local conditions to different protein structural forms during the elution and detection process. By optimizing conditions specifically for preserving and detecting aggregated forms versus monomeric forms, the method achieves high diagnostic accuracy for early disease stages where specific protein structural forms are present, enabling reliable early detection and stratification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate early-stage detection and stratification of neurodegenerative diseases by maintaining and detecting various protein forms, allowing for timely intervention and personalized treatment plans.
Implementation Method 1
binding some or all of the structural forms of the protein to a surface
Implementation Method 2
eluting at least a portion of the structural forms of the protein from the surface using conditions that reverse the binding interaction
Data Source
Figure 1~2
Figure 3a
Figure 3b
AI summary
The present invention relates to a method of detecting one or more tissue-derived aggregated proteins in a biological sample.